만성신장병환자에서 apixaban과 warfarin의 안전성 비교: 체계적 문헌고찰 및 메타분석
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 남재현 | - |
dc.contributor.author | 김채영 | - |
dc.contributor.author | 이유경 | - |
dc.contributor.author | 정다움 | - |
dc.contributor.author | 곽혜영 | - |
dc.contributor.author | 정지은 | - |
dc.date.accessioned | 2022-07-18T01:38:55Z | - |
dc.date.available | 2022-07-18T01:38:55Z | - |
dc.date.created | 2021-08-25 | - |
dc.date.issued | 2021-06 | - |
dc.identifier.issn | 1226-6051 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/108291 | - |
dc.description.abstract | Background: Patients with chronic kidney disease (CKD) are at a high risk of stroke-related morbidity, mortality, and bleeding. However, the overall risk/benefit of anticoagulant therapy among patients with CKD remains unclear. Methods: The MEDLINE, EMBASE, and CENTRAL databases were comprehensively searched until July 31, 2020, to investigate the safety and efficacy of apixaban in patients with stage 4 or 5 CKD, as compared with warfarin. The primary outcome was an incidence of major bleeding. Secondary outcomes included composite bleeding (major, clinically relevant, and minor bleeding), venous thromboembolism (VTE), stroke, and death. Results: In total, seven studies consisting of 10,816 patients were included. Compared with warfarin, apixaban was associated with a reduced risk of major bleeding (OR 0.49, 95% CI 0.41-0.58). In terms of composite bleeding, apixaban tended to pose a significantly lower risk than warfarin (OR 0.51, 95% CI 0.37-0.71). There was no difference between apixaban and warfarin with respect to the risk of stroke or death (stroke: OR 1.23, 95% CI 0.49-3.12; death: OR 0.73, 95% CI 0.45-1.18). Conclusion: Among patients with stage 4 or 5 CKD, the use of apixaban was associated with a lower risk of bleeding compared to warfarin and was also found to pose no excess risk of thromboembolic events. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 한국임상약학회 | - |
dc.title | 만성신장병환자에서 apixaban과 warfarin의 안전성 비교: 체계적 문헌고찰 및 메타분석 | - |
dc.title.alternative | Apixaban versus Warfarin in Patients with Chronic Kidney Disease; A Systematic Review and Meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 정지은 | - |
dc.identifier.doi | 10.24304/kjcp.2021.31.2.87 | - |
dc.identifier.bibliographicCitation | 한국임상약학회지, v.31, no.2, pp.87 - 95 | - |
dc.relation.isPartOf | 한국임상약학회지 | - |
dc.citation.title | 한국임상약학회지 | - |
dc.citation.volume | 31 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 87 | - |
dc.citation.endPage | 95 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002731215 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Chronic kidney disease | - |
dc.subject.keywordAuthor | apixaban | - |
dc.subject.keywordAuthor | warfarin | - |
dc.subject.keywordAuthor | bleeding | - |
dc.subject.keywordAuthor | thromboembolism | - |
dc.identifier.url | https://www.ekjcp.org//journal/view.html?doi=10.24304/kjcp.2021.31.2.87 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.